Rosen Law Firm has initiated a securities class action lawsuit against Ultragenyx Pharmaceutical Inc., targeting investors who purchased the company's common stock between August 3, 2023 and December 26, 2025. The litigation alleges that company executives made materially false and misleading statements regarding setrusumab's (UX 143) efficacy in reducing fracture rates among osteogenesis imperfecta patients, while simultaneously withholding information that increased bone density does not necessarily correlate with decreased fracture incidence.
The complaint centers on a purported disconnect between the drug candidate's mechanism of action and its actual clinical benefit. According to the filing, defendants allegedly promoted the therapeutic potential of setrusumab without adequately disclosing the limitations of bone density as a predictive marker for fracture risk reduction. This omission is characterized as material information that would have significantly influenced investment decisions during the specified period.
Investors who purchased Ultragenyx shares during the class period may qualify for compensation through the lawsuit. The firm has established April 6, 2026 as the deadline for investors to petition the court to serve as lead plaintiff, a designation that grants certain rights in oversight of the litigation. Legal counsel specializing in securities matters is advised for investors seeking to understand their options and potential remedies.